Enhancement supplement

AngioSoma Developing Male Enhancement Supplement

HOUSTON, TX, January 6, 2020 (GLOBE NEWSWIRE) – via NEWMEDIAWIRE – AngioSoma Inc. (OTC: SOAN) (“AngioSoma“or the”Society”) Today announced the development of Hi complete, a male erectile dysfunction (ED) product that contains extract of E. brevicornum, an all-natural phosphorodiesterase-5 inhibitor (biosimilar to Cialis and Viagra).

The male ED market is large and diverse and will require ingenuity and marketing skills from at least 50 million men who complain about male impotence. With proper advertising, we could probably reach 2-3 million customers per year.

“The successful development and commercialization of a biosimilar product to Cialis and Viagra can make a significant addition to our line of products that provide synergistic or complementary effects to an organ system of the body,” said Alex Blankenship, CEO of AngioSoma. “This new product will complement the rollout of our Muscles4U training enhancement products over the next year.”

ABOUT ANGIOSOMA, INC.

AngioSoma is a wellness company dedicated to bringing innovative, effective and high quality supplementation products to the medical, wellness and adult markets through our marketing subsidiary, SomaCeuticals ™. SomaCeuticals’ experienced team of industry pioneers and enterprising visionaries has acquired a diverse supplement offering, strong clinical, scientific and operational capabilities, and cutting-edge product research and development infrastructure to create products and brands you trust in a growing global market.

Learn more at www.muscles4U.com and http://muscles4u.blogstop.com. Stay up to date on Twitter: @ tweetmuscles4u, Instagram and Facebook.

NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes”, “expects to “,” Anticipate “or similar expressions. These forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. Moreover, describing anyone’s past success is no guarantee of future success. This press release is effective as of the date first stated above and the company assumes no responsibility for updating the information included in this document for events occurring after the date hereof.

CONTACT

AngioSoma, Inc.

Alex blankenship

Alex@AngioSoma.com

(832) 781- 8521


Source link

Leave a Reply

Your email address will not be published.